The Dementia Associated With Alzheimer’s Disease drugs in development market research report provides comprehensive information on the therapeutics under development for Dementia Associated With Alzheimer’s Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Dementia Associated With Alzheimer’s Disease. Buy the report here.

Smarter leaders trust GlobalData

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Dementia Associated With Alzheimer’s Disease and features dormant and discontinued products.

GlobalData tracks 54 drugs in development for Dementia Associated With Alzheimer’s Disease by 49 companies/universities/institutes. The top development phase for Dementia Associated With Alzheimer’s Disease is phase ii with 13 drugs in that stage. The Dementia Associated With Alzheimer’s Disease pipeline has 51 drugs in development by companies and three by universities/ institutes. Some of the companies in the Dementia Associated With Alzheimer’s Disease pipeline products market are: Whan In Pharm, Eisai and Actinogen Medical.

The key targets in the Dementia Associated With Alzheimer’s Disease pipeline products market include Acetylcholinesterase (Acetylcholine Hydrolase or Yt Blood Group or Apoptosis Related Acetylcholinesterase or ACHE or EC 3.1.1.7), Glutamate Ionotropic Receptor NMDA Type Subunit (NMDAR or GRIN), and Microtubule Associated Protein Tau (Neurofibrillary Tangle Protein or Paired Helical Filament Tau or MAPT).

The key mechanisms of action in the Dementia Associated With Alzheimer’s Disease pipeline product include Acetylcholinesterase (Acetylcholine Hydrolase or Yt Blood Group or Apoptosis Related Acetylcholinesterase or ACHE or EC 3.1.1.7) Inhibitor with nine drugs in Pre-Registration. The Dementia Associated With Alzheimer’s Disease pipeline products include 12 routes of administration with the top ROA being Oral and eight key molecule types in the Dementia Associated With Alzheimer’s Disease pipeline products market including Small Molecule, and Cell Therapy.

Dementia Associated With Alzheimer’s Disease overview

Alzheimer’s disease (AD) is the most common cause of dementia. AD is a progressive neurodegenerative disorder characterized by cognitive decline, memory loss, and changes in behavior and thinking skills that interfere with daily functioning. Early symptoms may include mild forgetfulness, difficulty recalling recent events or information, and trouble with problem-solving or complex tasks. One of the hallmark features of AD is the impairment of memory, particularly short-term memory. Individuals may have trouble remembering recent conversations, names, or important dates. As the disease progresses, individuals may experience changes in behavior, mood swings, confusion, disorientation, difficulty in following conversations, and problems with language (aphasia). They may also withdraw from social activities and exhibit changes in personality. Alzheimer’s disease is associated with the accumulation of abnormal protein deposits in the brain, including beta-amyloid plaques and tau tangles, which disrupt communication between brain cells, leading to their degeneration and death.

For a complete picture of Dementia Associated With Alzheimer’s Disease’s pipeline drug market, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.